uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A High Ductal Flow Velocity is Associated with Successful Pharmacological Closure of Patent Ductus Arteriosus in Infants 22-27 Weeks Gestational Age
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Pediatrics. (Perinatal, neonatal och barnkardiologisk forsning/Hellström-Westas)ORCID iD: 0000-0001-8382-8687
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Pediatrics. (Perinatal, neonatal och barnkardiologisk forsning/Hellström-Westas)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Pediatrics. (Perinatal, neonatal och barnkardiologisk forsning/Hellström-Westas)
2012 (English)In: Critical Care Research and Practice, ISSN 2090-1305, E-ISSN 2090-1313, p. 715265-Article in journal (Refereed) Published
Abstract [en]

Objective:

To identify factors affecting closure of patent ductus arteriosus (PDA) in newborn infants born at 22-27 weeks gestational age (GA) during pharmacological treatment with cyclooxygenase inhibitors.

Method:

Infants born at 22-27 weeks of GA between January 2006 and December 2009 who had been treated pharmacologically for PDA were identified retrospectively. Medical records were assessed for clinical, ventilatory and outcome parameters. Echocardiographic examinations during treatment were reviewed.

Results:

Fifty-six infants were included in the study. Overall success rate of ductal closure with pharmacological treatment was 52%. Infants whose PDA was successfully closed had a higher GA (25+4 weeks vs. 24+3 weeks; P=0.047), and a higher pre-treatment left to right maximal ductal flow velocity (1.6 m/s vs. 1.1 m/s; P=0.023). Correcting for GA, preeclampsia, antenatal steroids, and age at treatment start, a higher maximal ductal flow velocity was still associated with successful ductal closure (OR 3.04, p=0.049).

Conclusion:

Maximal ductal flow velocity was independently associated with success of PDA treatment.

Place, publisher, year, edition, pages
2012. p. 715265-
Keywords [en]
patent ductus arteriosus, preterm, cyclooxygenase inhibitors, echocardiography
National Category
Medical and Health Sciences Pediatrics
Identifiers
URN: urn:nbn:se:uu:diva-187783DOI: 10.1155/2012/715265OAI: oai:DiVA.org:uu-187783DiVA, id: diva2:575603
Funder
Swedish Heart Lung Foundation, 20100033Available from: 2012-12-10 Created: 2012-12-10 Last updated: 2019-02-04Bibliographically approved
In thesis
1. Persistent ductus arteriosus in extremely preterm infants
Open this publication in new window or tab >>Persistent ductus arteriosus in extremely preterm infants
2019 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Patent ductus arteriosus (PDA) is common in infants born <28 weeks gestational age (GA) and associated with significant morbidity. Despite extensive research efforts, the indications for PDA treatment remain controversial. The aims of these studies were to gain knowledge of factors affecting ductal closure during the early postnatal period and provide better means for identification of preterm infants that may benefit from PDA treatment.

In Paper I, infants born <28 weeks GA and pharmacologically treated for PDA were retrospectively identified and their echocardiographic examinations were reviewed. Twenty-nine (52%) infants successfully closed and 27 (48%) infants failed to close PDA during treatment. High maximal ductal flow velocity (Vmax) was independently associated with closure (OR 3.04, p=0.049).

Paper II prospectively included infants born <28 weeks GA and assessed early respiratory, circulatory and echocardiographic parameters. PDA was persistent in 18 (30%) and ultimately closed or insignificant in 42 (70%) infants. Echocardiographic criteria for hemodynamically significant PDA on days 2-7 did not predict persistent PDA (p=1.000). Mechanical ventilation (p=0.025), high mean airway pressure (p=0.020) and low Vmax (p=0.024) during day two were associated with future persistent PDA.

Blood samples were obtained during the second day of life from 47 of the infants in Paper II and serum markers previously associated with PDA or factors affecting PDA were analyzed for Paper III. Inflammatory markers and erythropoietin (EPO) were elevated in infants with future persistent PDA. EPO levels were also higher in infants that did not close PDA during pharmacological treatment.

In Paper IV, 44 infants born <28 weeks GA with surgically ligated PDA were retrospectively compared to non-surgically treated controls. Ligated infants had larger ductal diameter prior to, and lack of diameter decrease after pharmacological treatment for PDA (p=0.048 and p=0.022 respectively), and higher incidence of severe bronchopulmonary dysplasia (p=0.025). Longer periods with invasive ventilation was independently associated with ligation (OR 1.04, p=0.018).

In conclusion, early hsPDA do not predict persistence of ductus arteriosus in extremely preterm infants, but Vmax and EPO are promising early markers for prediction of persistence and should be subjects of future studies.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2019. p. 73
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 1539
Keywords
Echocardiography, Erythropoietin. Extremely preterm infants, Maximal ductal flow velocity, Patent ductus arteriosus, Persistent ductus arteriosus.
National Category
Pediatrics
Research subject
Pediatrics
Identifiers
urn:nbn:se:uu:diva-375550 (URN)978-91-513-0572-1 (ISBN)
Public defence
2019-03-22, Rosénsalen, Akademiska sjukhuset, Ingång 95/96, NBV, Uppsala, 09:15 (Swedish)
Opponent
Supervisors
Available from: 2019-02-27 Created: 2019-02-04 Last updated: 2019-03-18

Open Access in DiVA

Olsson fulltext(1715 kB)201 downloads
File information
File name FULLTEXT01.pdfFile size 1715 kBChecksum SHA-512
38d241e5e901aacfee5a1a477c565ba764543dbf5d7337150065d70cbf4eea3f86c97b563f213332af17aecfc0f95c8dca0260bfc38e3af66e086e7b20e374c1
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Olsson, Karl WilhelmJonzon, AndersSindelar, Richard

Search in DiVA

By author/editor
Olsson, Karl WilhelmJonzon, AndersSindelar, Richard
By organisation
Pediatrics
In the same journal
Critical Care Research and Practice
Medical and Health SciencesPediatrics

Search outside of DiVA

GoogleGoogle Scholar
Total: 201 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 457 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf